Please assess the completion status of the following clinical trial:

Trial Title: 16.0040 Ankylosing Spondylitis Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria: - Subjects completing 24 weeks of study drug in protocol 16.0037 qualify to enroll into this study Other patients to meet the following criteria:~* Negative pregnancy test~* Subjects agree to use appropriate contraception throughout study~* Should be able to self-inject study drug or have someone who can do so~* Capable of understanding protocol and willing to provide written informed consent~Exclusion Criteria:~* Any change in NSAID or prednisone dose within 2 weeks of baseline~* Any change in hydroxychloroquine, sulfasalazine, or MTX dose within 4 weeks of baseline~* Use of DMARDs other than those mentioned above, within 4 weeks of enrollment~* Previous receipt of ani-TNF agents, other than etanercept~* Receipt of any other investigational drug within 30 days of baseline~* Grade 3 or 4 adverse event attributed to etanercept which recurred when etanercept was resumed~* Abnormality in chemistry or hematology profiles or significant concurrent medical events.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All subjects (Type: EXPERIMENTAL): 257 subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).